Alliance Pharma PLC
LSE:APH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (10.9), the stock would be worth GBX64.7 (0% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.9 | GBX64.7 |
0%
|
| 3-Year Average | 10.9 | GBX64.7 |
0%
|
| 5-Year Average | 12.4 | GBX73.58 |
+14%
|
| Industry Average | 0 | GBX0.19 |
-100%
|
| Country Average | 0 | GBX0.22 |
-100%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
A
|
Alliance Pharma PLC
LSE:APH
|
349.7m GBP | 10.9 | -32.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 143.1 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 28.9 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 35.5 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 18.6 | 19 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 24.7 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 43.2 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 22.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 11.6 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 344.9 |
Other Multiples
Alliance Pharma PLC
Glance View
Alliance Pharma Plc is a holding company, which engages in the acquisition, marketing, and distribution of healthcare and pharmaceutical products. The company is headquartered in Chippenham, Wiltshire and currently employs 255 full-time employees. The company went IPO on 2001-11-22. The firm is primarily engaged in the acquisition, marketing and distribution of healthcare and pharmaceutical products. The company is focused on two areas, which include Consumer Healthcare brands and Prescription Medicines. The Company’s Consumer Healthcare brands include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse and Aloclair. Its Prescription Medicines include Hydromol, Flamma Franchise and Forceval. Its brands also include Ashton & Parsons and Anbesol. The Company’s products include Alliance Calcium Syrup, Amantadine hydrochloride, Aiweidi, Biodermatin, Biotaches, Buccastem M, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Gen-Ongles, Irenat, ISIB, Isocarboxazid, Jonctum, Kelo-Stretch, Lypsyl, Lefuzhi, Malunjunshe, MolluDab, Menadiol, Neostigmine and Nu-Seals. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).
